Please login to the form below

Not currently logged in
Email:
Password:

Metrion Biosciences establishes scientific advisory board

The board will provide scientific oversight and strategic advice to Metrion

Contract research organisation and drug discovery business Metrion Biosciences has established a scientific advisory board, which will provide strategic scientific guidance to the company.

The new board will be chaired by Dr Keith McCullagh, Metrion’s non-executive chairman, and its members will include Dr David Reynolds, chief scientific officer at Alzheimer’s Research UK.

Dr Reynolds has served in numerous positions at Merck, Lundbeck and Pfizer.

Dr Tom Colatsky also joins the board following over 30 years of drug discovery experience, including seven years in senior US Food and Drug Admistration positions.

The board will also comprise of Professor Annette Dolphin, Professor Chris Denning and Marc Rogers, who is currently chief scientific officer at Metrion.

20th February 2018

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics